Logo

BeyondSpring Submits NDA to the US FDA and China NMPA for Plinabulin to Prevent CT-Induced Neutropenia

Share this

BeyondSpring Submits NDA to the US FDA and China NMPA for Plinabulin to Prevent CT-Induced Neutropenia

Shots:

  • The NDA submission is based on data from P-III PROTECTIVE-2 study evaluating Plinabulin + Neulasta vs Neulasta alone for the prevention of CIN
  • The study met its 1EPs and 2EPs with an improvement in the rate of prevention of grade 4 neutropenia from 13.6% to 31.5%- the 2 EPs include DSN and ANC. The results demonstrated superior CIN prevention benefit- reduced clinical complications such as incidence- severity of febrile neutropenia and duration of hospitalization for FN patients- well- tolerated- 20% reduction of grade 4 TEAEs
  • The NDA submissions will include 5 trials in 1200 patients to show consistent CIN prevention in various CT regimens and cancers

  Ref: Globe Newswire | Image: Beyond Spring Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions